The polycythemia market is projected to reach $6.53B by 2030 at 7.0% CAGR, driven by JAK2-targeted therapies, personalized treatments, and advanced hematocrit monitoring.
Read More
The plant-derived analgesics market is projected to reach $5.06B by 2030 at 8.4% CAGR, driven by natural therapeutics adoption, cannabinoid growth, and advanced botanical pain therapies.
Read More
The penicillin API market is projected to reach $12.34 billion by 2030 at a 5.1% CAGR, driven by rising infections, generic antibiotic expansion, and advanced high-purity manufacturing processes.
Read More
The palmoplantar keratoderma market is projected to reach $1.13 billion by 2030 at a 5.2% CAGR, driven by targeted dermatology drugs, biologics, and advanced genetic diagnostics.
Read More
The neuroendocrine prostate cancer market is projected to reach $1.6 billion by 2030 at an 8.7% CAGR, driven by precision oncology, biomarkers, and targeted therapies.
Read More
The nervous system API market is projected to reach $334.12 billion by 2030 at a 5.6% CAGR, driven by CNS therapies, neurodegenerative treatments, and high-purity API demand.
Read More
The monogenetic disease therapy market is set to reach $45.58 billion by 2030 at a 10.0% CAGR, driven by gene editing advances and precision genetic treatments.
Read More
The MAPK inhibitors market is projected to reach $5.22 billion by 2030 at an 11.3% CAGR, driven by targeted oncology therapies and personalized cancer care growth.
Read More
The mRNA manufacturing service market is projected to reach $12.97 billion by 2030 at a 16.2% CAGR, driven by therapy trials, outsourcing demand, and GMP-scale production.
Read More
The mRNA and next-generation vaccine platforms market is set to reach $82.61 billion by 2030 at a 15.8% CAGR, driven by cancer vaccines and rapid platform innovation.
Read More